Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. Compounds derived from Shattuck’s ARC platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the TNF CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing its second proprietary platform, Gamma Delta T Cell Engagers (GADLEN™), a novel approach designed to bridge gamma delta T cells to tumor antigens for the treatment of cancer.
|Price||Change||Volume||52 Week High||52 Week Low|
Data Provided by Refinitiv. Minimum 15 minutes delayed.